JP2000510107A - ウイルス性及び分子性病原体不含の生物学的材料及びその製造方法 - Google Patents
ウイルス性及び分子性病原体不含の生物学的材料及びその製造方法Info
- Publication number
- JP2000510107A JP2000510107A JP09538394A JP53839497A JP2000510107A JP 2000510107 A JP2000510107 A JP 2000510107A JP 09538394 A JP09538394 A JP 09538394A JP 53839497 A JP53839497 A JP 53839497A JP 2000510107 A JP2000510107 A JP 2000510107A
- Authority
- JP
- Japan
- Prior art keywords
- ligand
- biological material
- pathogen
- receptor
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000052769 pathogen Species 0.000 title claims abstract description 148
- 239000012620 biological material Substances 0.000 title claims abstract description 120
- 230000003612 virological effect Effects 0.000 title claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 title claims description 14
- 239000003446 ligand Substances 0.000 claims abstract description 111
- 238000000034 method Methods 0.000 claims abstract description 109
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 90
- 241000700605 Viruses Species 0.000 claims description 109
- 108060003951 Immunoglobulin Proteins 0.000 claims description 50
- 102000018358 immunoglobulin Human genes 0.000 claims description 50
- 239000000706 filtrate Substances 0.000 claims description 28
- 241000125945 Protoparvovirus Species 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 230000009467 reduction Effects 0.000 claims description 21
- 238000000926 separation method Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 16
- 230000002779 inactivation Effects 0.000 claims description 15
- 102000029797 Prion Human genes 0.000 claims description 13
- 108091000054 Prion Proteins 0.000 claims description 13
- 239000012141 concentrate Substances 0.000 claims description 13
- 230000000717 retained effect Effects 0.000 claims description 13
- 238000004062 sedimentation Methods 0.000 claims description 12
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 12
- 108010054218 Factor VIII Proteins 0.000 claims description 11
- 102000001690 Factor VIII Human genes 0.000 claims description 11
- 239000000910 agglutinin Substances 0.000 claims description 11
- 229960000182 blood factors Drugs 0.000 claims description 11
- 229960000301 factor viii Drugs 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 102100036537 von Willebrand factor Human genes 0.000 claims description 11
- 101710186708 Agglutinin Proteins 0.000 claims description 10
- 101710146024 Horcolin Proteins 0.000 claims description 10
- 101710189395 Lectin Proteins 0.000 claims description 10
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 10
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 10
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 9
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 7
- 108010076282 Factor IX Proteins 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 238000004220 aggregation Methods 0.000 claims description 7
- 230000002776 aggregation Effects 0.000 claims description 7
- 229960004222 factor ix Drugs 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 102000004506 Blood Proteins Human genes 0.000 claims description 6
- 108010017384 Blood Proteins Proteins 0.000 claims description 6
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 6
- 108010023321 Factor VII Proteins 0.000 claims description 6
- 108010018927 conglutinin Proteins 0.000 claims description 6
- QCUFYOBGGZSFHY-UHFFFAOYSA-N depsidomycin Chemical compound O=C1C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC=O)C(C)CC)C(C)OC(=O)C2CCCNN2C(=O)C(CC(C)C)NC(=O)C2CCCNN21 QCUFYOBGGZSFHY-UHFFFAOYSA-N 0.000 claims description 6
- 229940012413 factor vii Drugs 0.000 claims description 6
- 108010074864 Factor XI Proteins 0.000 claims description 5
- 230000004931 aggregating effect Effects 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 108090001090 Lectins Proteins 0.000 claims description 4
- 102000004856 Lectins Human genes 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 101800004937 Protein C Proteins 0.000 claims description 4
- 102000017975 Protein C Human genes 0.000 claims description 4
- 229940096437 Protein S Drugs 0.000 claims description 4
- 102000029301 Protein S Human genes 0.000 claims description 4
- 108010066124 Protein S Proteins 0.000 claims description 4
- 108010094028 Prothrombin Proteins 0.000 claims description 4
- 101800001700 Saposin-D Proteins 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000002523 lectin Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 244000309711 non-enveloped viruses Species 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229960000856 protein c Drugs 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 108010014173 Factor X Proteins 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 244000052613 viral pathogen Species 0.000 claims description 3
- 229920003170 water-soluble synthetic polymer Polymers 0.000 claims description 3
- 108010062580 Concanavalin A Proteins 0.000 claims description 2
- 102000004204 Fascin Human genes 0.000 claims description 2
- 108090000786 Fascin Proteins 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 239000008394 flocculating agent Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000013077 target material Substances 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 73
- 241000709721 Hepatovirus A Species 0.000 description 34
- 230000007717 exclusion Effects 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 238000001914 filtration Methods 0.000 description 20
- 241000711549 Hepacivirus C Species 0.000 description 19
- 238000001728 nano-filtration Methods 0.000 description 16
- 239000007858 starting material Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 241000991587 Enterovirus C Species 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 230000027455 binding Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 7
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000012460 protein solution Substances 0.000 description 6
- 238000009295 crossflow filtration Methods 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 241000531123 GB virus C Species 0.000 description 4
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004411 Antithrombin III Human genes 0.000 description 3
- 108090000935 Antithrombin III Proteins 0.000 description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 241000724709 Hepatitis delta virus Species 0.000 description 3
- 241000702617 Human parvovirus B19 Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229960005348 antithrombin iii Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940009550 c1 esterase inhibitor Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940012426 factor x Drugs 0.000 description 2
- -1 for example Proteins 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 101710133652 Lectin-like protein Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000538 anti-polioviral effect Effects 0.000 description 1
- 108010083526 asialo-von Willebrand Factor Proteins 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 244000000024 mild pathogen Species 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000013621 viresolve pro solution Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0078096A AT403477B (de) | 1996-04-30 | 1996-04-30 | Biologisches material frei von viralen und molekularen pathogenen und verfahren zur herstellung |
| AT780/96 | 1996-04-30 | ||
| PCT/AT1997/000075 WO1997040861A1 (fr) | 1996-04-30 | 1997-04-23 | Materiau biologique depourvu d'agents pathogenes viraux et moleculaires et son procede de production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000510107A true JP2000510107A (ja) | 2000-08-08 |
Family
ID=3499569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09538394A Pending JP2000510107A (ja) | 1996-04-30 | 1997-04-23 | ウイルス性及び分子性病原体不含の生物学的材料及びその製造方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0900089A1 (fr) |
| JP (1) | JP2000510107A (fr) |
| AT (1) | AT403477B (fr) |
| AU (1) | AU731048B2 (fr) |
| CA (1) | CA2253300A1 (fr) |
| IL (1) | IL126810A0 (fr) |
| NO (1) | NO984979L (fr) |
| WO (1) | WO1997040861A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620629B1 (en) | 1997-02-21 | 2003-09-16 | The Regents Of The University Of California | Method for detecting prions |
| US6720355B2 (en) | 1997-02-21 | 2004-04-13 | The Regents Of The University Of California | Sodium dodecyl sulfate compositions for inactivating prions |
| US6221614B1 (en) * | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
| US6617119B2 (en) | 1997-02-21 | 2003-09-09 | The Regents Of The University Of California | Assay for specific strains of multiple disease related conformations of a protein |
| AU726999B2 (en) * | 1997-06-13 | 2000-11-30 | Baxter Aktiengesellschaft | Process for reducing the concentration of viral and molecular pathogens in a biological material |
| DE19752898A1 (de) * | 1997-11-28 | 1999-08-05 | Centeon Pharma Gmbh | Verfahren zum Nachweis hoher Vierenkonzentrationen im Blutplasma und/oder Blutserum mittels der Polymerasekettenreaktion |
| US5977324A (en) * | 1998-02-20 | 1999-11-02 | The Regents Of The University Of California | Process for concentrating protein with disease-related conformation |
| WO2000012103A1 (fr) * | 1998-08-31 | 2000-03-09 | Ambrus Julian L | Procede d'elimination du sang de virus hiv et d'autres virus |
| CA2392797A1 (fr) * | 1999-12-02 | 2001-06-07 | V.I. Technologies, Inc. | Procede d'identification d'un ligand destine a une molecule cible |
| WO2002062956A2 (fr) * | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Retrait chimiomagnetique du cytomegalovirus et des cellules infectees par ce virus |
| CA2516403C (fr) | 2003-01-17 | 2014-08-12 | Aethlon Medical, Inc. | Procede de suppression de virus dans le sang par hemodialyse a affinite pour les lectines |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896218A (en) * | 1972-07-13 | 1975-07-22 | Research Corp | Radiommunoassay determining the hepatitis associated antigen content of blood |
| ZA838856B (en) * | 1982-12-02 | 1984-07-25 | Usv Pharma Corp | Hepatitis b and non-a-non-b-safe biological products |
| JPS63243032A (ja) * | 1987-03-27 | 1988-10-07 | Green Cross Corp:The | トロンビンの加熱処理方法 |
| EP0477302B1 (fr) * | 1989-06-15 | 1995-02-01 | SMITH, William I. Jr. | Appareil rendant inactifs les agents infectieux dans les fluides biologiques, et resistant a la coagulation de ceux-ci |
| ES2131504T3 (es) * | 1990-02-20 | 1999-08-01 | Baxter Int | Trombina humana purificada viricamente segura. |
| EP0447984A1 (fr) * | 1990-03-20 | 1991-09-25 | Abbott Laboratories | Globuline hyperimmune contre le virus de l'hépatite C et son procédé de préparation |
| DE4125625C2 (de) * | 1991-08-02 | 1999-12-02 | Octapharma Ag Glarus | Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen |
| DE4142908C2 (de) * | 1991-12-24 | 1994-02-10 | Octapharma Ag Glarus | Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB) |
| EP0679405A1 (fr) * | 1994-04-25 | 1995-11-02 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Procédé pour séparer les virus contenus dans une solution de protéine |
| AT406019B (de) * | 1995-05-08 | 2000-01-25 | Immuno Ag | Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate |
-
1996
- 1996-04-30 AT AT0078096A patent/AT403477B/de not_active IP Right Cessation
-
1997
- 1997-04-23 CA CA002253300A patent/CA2253300A1/fr not_active Abandoned
- 1997-04-23 WO PCT/AT1997/000075 patent/WO1997040861A1/fr not_active Application Discontinuation
- 1997-04-23 AU AU25612/97A patent/AU731048B2/en not_active Ceased
- 1997-04-23 EP EP97917167A patent/EP0900089A1/fr not_active Withdrawn
- 1997-04-23 JP JP09538394A patent/JP2000510107A/ja active Pending
- 1997-04-23 IL IL12681097A patent/IL126810A0/xx unknown
-
1998
- 1998-10-26 NO NO984979A patent/NO984979L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO984979L (no) | 1998-12-23 |
| AU731048B2 (en) | 2001-03-22 |
| AU2561297A (en) | 1997-11-19 |
| NO984979D0 (no) | 1998-10-26 |
| ATA78096A (de) | 1997-07-15 |
| EP0900089A1 (fr) | 1999-03-10 |
| AT403477B (de) | 1998-02-25 |
| WO1997040861A1 (fr) | 1997-11-06 |
| IL126810A0 (en) | 1999-08-17 |
| CA2253300A1 (fr) | 1997-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Burnouf et al. | Nanofiltration of plasma‐derived biopharmaceutical products | |
| JP4031833B2 (ja) | プリオンのクロマトグラフィー除去方法 | |
| RU2337109C2 (ru) | ПРЕПАРАТ ИММУНОГЛОБУЛИНА IgG И СПОСОБ ЕГО ПОЛУЧЕНИЯ | |
| ES2295308T3 (es) | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. | |
| JP2008500959A (ja) | ウイルスについて安全な免疫グロブリンの製造方法 | |
| JP2000510107A (ja) | ウイルス性及び分子性病原体不含の生物学的材料及びその製造方法 | |
| Yokoyama et al. | Removal of small non‐enveloped viruses by nanofiltration | |
| JP2002500164A (ja) | ウイルスクリアランス法 | |
| US6391657B1 (en) | Removal of viruses from protein solutions by ultrafiltration | |
| CA1066191A (fr) | Vaccin contre l'hepatite b | |
| Bos et al. | Virus Validation of PH 4-treated Human Immunoglobulin Produced by the Cohn Fractionation Process | |
| US7655233B2 (en) | Optimal placement of a robust solvent/detergent process post viral ultrafiltration of an immune gamma globulin | |
| Caballero et al. | Viral safety characteristics of Flebogamma® DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin | |
| US6407212B1 (en) | Method for the removal of causative agent(s) of transmissible spongiform encephalopathies from protein solutions | |
| Van Holten et al. | Incorporation of an additional viral‐clearance step into a human immunoglobulin manufacturing process | |
| Koenderman et al. | Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step | |
| Morgenthaler | Securing viral safety for plasma derivatives | |
| RU2728724C2 (ru) | Способ получения вирусбезопасного раствора иммуноглобулина g человека для внутримышечного введения | |
| JP2002505674A (ja) | 生物材料中のウイルスおよび分子病原体を除去する方法 | |
| Alarifi | Nanofiltration for blood products | |
| Burnouf et al. | Strategy of virus removal/inactivation of plasma-derived products: Interest of nanofiltration as a new virus elimination method | |
| Aranha-Creado | Ensuring Virological Safety of Biologicals: Virus Removal from Biological Fluids by Filtration | |
| JP2000319294A (ja) | 生物由来高分子溶液精製方法 | |
| Foster | Plasma fractionation | |
| Foster et al. | 20 FRACTIONATED PRODUCTS |